{
"id":"mk19_a_gm_t42",
"number":42,
"bookId":"gm",
"title":{
"__html":"Risk-Enhancing Factors for Clinician-Patient Risk Discussion"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"34620c",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 42. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gm_t42"
}
]
},
"Risk-Enhancing Factors for Clinician-Patient Risk Discussion"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f615ee",
"class":"cell txt l",
"children":[
"Family history of premature ASCVD (males, age <55 y; females, age <65 y)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"239c43",
"class":"cell txt l",
"children":[
"Primary hypercholesterolemia (LDL cholesterol 160-189 mg/dL [4.14-4.90 mmol/L]; non-HDL cholesterol 190-219 mg/dL [4.92-5.67 mmol/L])",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8bcb87",
"class":"cell txt l",
"children":[
"Metabolic syndrome (increased waist circumference, elevated triglycerides [>150 mg/dL {1.69 mmol/L}], elevated blood pressure, elevated glucose, and low HDL cholesterol [<40 mg/dL {1.04 mmol/L} in men; <50 mg/dL {1.29 mmol/L} in women] are factors; tally of three makes the diagnosis)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"916922",
"class":"cell txt l",
"children":[
"Chronic kidney disease (eGFR 15-59 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" with or without albuminuria; not treated with dialysis or kidney transplantation)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"555a9a",
"class":"cell txt l",
"children":[
"Chronic inflammatory conditions, such as psoriasis, RA, or HIV/AIDS"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e2b3a8",
"class":"cell txt l",
"children":[
"History of premature menopause (before age 40 y) and history of pregnancy-associated conditions that increase later ASCVD risk, such as preeclampsia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"037f93",
"class":"cell txt l",
"children":[
"High-risk race/ethnicities (e.g., South Asian ancestry)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aafc4e",
"class":"cell txt l",
"children":[
"Lipid/biomarkers: Associated with increased ASCVD risk"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6a8727",
"class":"cell txt li",
"children":[
"Persistently",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
" elevated, primary hypertriglyceridemia (≥175 mg/dL [1.98 mmol/L])"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6f16a7",
"class":"cell txt li",
"children":[
"If measured:"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"58b3a3",
"class":"cell txt lii",
"children":[
"1. Elevated high-sensitivity C-reactive protein (≥2.0 mg/L)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f7df60",
"class":"cell txt lii",
"children":[
"2. Elevated Lp(a): A relative indication for its measurement is family history of premature ASCVD. An Lp(a) ≥50 mg/dL (0.50 g/L) or ≥125 nmol/L constitutes a risk-enhancing factor, especially at higher levels of Lp(a)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8e10bf",
"class":"cell txt lii",
"children":[
"3. Elevated apoB ≥130 mg/dL (1.3 g/L): A relative indication for its measurement would be triglycerides ≥200 mg/dL (2.26 mmol/L). A level ≥130 mg/dL (1.3 g/L) corresponds to an LDL cholesterol >160 mg/dL (4.14 mmol/L) and constitutes a risk-enhancing factor"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10b8f0",
"class":"cell txt lii",
"children":[
"4. ABI <0.9"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ABI = ankle-brachial index; apoB = apolipoprotein B; ASCVD = atherosclerotic cardiovascular disease; eGFR = estimated glomerular filtration rate; Lp(a) = lipoprotein(a); RA = rheumatoid arthritis."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Optimally, three determinations."
],
[
"Reproduced with permission from Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082-143. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30586774",
"target":"_blank"
},
"children":[
"PMID: 30586774"
]
},
" doi:10.1161/CIR.0000000000000625. ©2018, American Heart Association, Inc."
]
]
}